A Retrospective Study Evaluating Safety And Feasibility Of Adjuvant Chemotherapy With 6-Week Cycles Versus 3-Week Cycles S-1 For Patients With Advanced Gastric Cancer Curatively Resected With D2 Lymph Node Dissection.

e15080 Background: Adjuvant chemotherapy with 6-week cycles S-1 was confirmed to improve overall survival and relapse-free survival in patient with advanced gastric cancer curatively resected with D2 lymph node dissection. We conducted a retrospective trial evaluating safety and feasibility of adjuvant chemotherapy with 6-week cycles versus 3-week cycles S-1 in patients with stage II/III gastric cancer who had undergone D2 gastrectomy. Methods: We retrospectively evaluated medical records of 83 patients with gastric cancer who had received adjuvant S-1 following curative D2 gastrectomy. Adjuvant S-1 was administered at a dose of 40 mg/m2 twice daily for 4 weeks followed by 2 weeks of rest (6-week cycles) or 2 weeks followed by 1 week of rest (3-week cycles) for 1 year. Results: 6-week cycles and 3-week cycles included 39 and 44 patients, respectively. Median number of cycles was eight (range, 1-9) in the 6-week cycles and 15 (range, 1-17) in the 3-week cycles. The number of patients who completed the pres...